Amnio Technology: Advancing the Science of Regenerative Medicine

Toward the end of the 20th century, scientists discovered the therapeutic value of the amniotic tissue, and since then, its expanded use and applications, specifically for wound care, have taken phenomenal strides. However, there are numerous potential applications that are yet to be demonstrated in clinical settings. Headquartered in Phoenix, AZ, Amnio Technology is a global leader in the development and distribution of amniotic tissue allografts. This company is introducing several unmet potential applications of amniotic allografts to the industry and is investing in creating products with pharma-compliant quality. As newer regulations rollout, Amnio will be in a better position to demonstrate not only from a “performance in the market” perspective but also from a regulatory standpoint.

Amniotic tissues are composed of elements that are essential for fetal growth and development, such as extracellular matrix proteins, growth factors, cytokines, carbohydrates, and hyaluronic acid, to name a few. By making considerable advancements in the use of these unique allografts, Amnio Technology is improving the quality of life for patients in need of better wound care. Explaining how Amnio Technology is achieving this, Larry Macal, Director of Operations, Amnio Technology, says, “We have invested heavily in upgrading our contract manufacturing facility and processes, bringing in a level of automation at appropriate places.” Amnio Technology focuses on a combination of technical and supply chain parameters and evaluates ways to rapidly bring the tissue from manufacturing, through in-process and post-process monitoring, all the way through to cryogenic storage. Through their formulation procedure and most importantly, the reduced time that is taken for processing the product, the shelf life and efficacy is enhanced.